Head to Head Analysis: Artiva Biotherapeutics (NASDAQ:ARTV) & Compugen (NASDAQ:CGEN)

Artiva Biotherapeutics (NASDAQ:ARTV) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and target prices for Artiva Biotherapeutics and Compugen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	0	0	6	0	3.00
Compugen	0	0	2	0	3.00

Artiva Biotherapeutics presently has a consensus price target of $21.00, indicating a potential upside of 437.08%. Compugen has a consensus price target of $4.00, indicating a potential upside of 55.64%. Given Artiva Biotherapeutics’ higher probable upside, equities research analysts plainly believe Artiva Biotherapeutics is more favorable than Compugen.

Earnings and Valuation

This table compares Artiva Biotherapeutics and Compugen”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
Compugen	$33.46 million	6.85	-$18.75 million	$0.02	128.50

Artiva Biotherapeutics has higher earnings, but lower revenue than Compugen.

Profitability

This table compares Artiva Biotherapeutics and Compugen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	N/A	N/A
Compugen	2.67%	2.62%	1.36%

Insider & Institutional Ownership

12.2% of Compugen shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Compugen beats Artiva Biotherapeutics on 6 of the 8 factors compared between the two stocks.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.